title: Fas ligand is expressed on human squamous cell carcinomas of the head and neck, and it promotes apoptosis of T lymphocytes.
abstract: Recent reports have variously described expression of Fas ligand (FasL) or its absence in human tumors. The importance of the Fas-FasL mechanism for the immune evasion by tumors provided a strong rationale for the examination of FasL expression and function in squamous cell carcinoma of the head and neck (SCCHN), which is one of the most immunosuppressive human cancers. Using immunostaining or immunoblotting, SCCHN cell lines and tumor biopsies were examined for the presence of the components of the Fas-FasL pathway and found to express Fas, as well as both the full-length and cleaved forms of FasL. By reverse transcription-PCR, mRNA for FasL and Fas were detected in all SCCHN tested, and cross-hybridization to radioactive Fas and FasL cDNA probes confirmed the specificity of amplification. To demonstrate that FasL expressed on cell surface of SCCHN cells was biologically active, various SCCHN lines were coincubated with the Fas-sensitive Jurkat T-cell lines or activated peripheral blood mononuclear cells. Tumor-induced apoptosis of T cells was dependent on the ratio of tumor cells: lymphocytes. It was significantly but only partially inhibited by neutralizing antibodies to FasL and antagonistic antibodies to FasR. Tumor-induced apoptosis was enhanced by the pretreatment of tumor cells with metalloproteinase inhibitors, which increased expression of FasL on tumor cells. Supernatants of tumor cells transduced with FasL also induced apoptosis of Jurkat cells. Thus, coincubation of SCCHN with Fas-sensitive lymphocytes can induce apoptosis of these lymphocytes, and the Fas/FasL pathway appears to be responsible, at least in part, for tumor-induced lymphocyte death. The data suggest that the Fas/FasL pathway is potentially immunosuppressive and may be involved in the escape of human carcinoma cells from immune destruction.
authors.affiliation: University of Pittsburgh Cancer Institute, and Department of Otolaryngology, University of Pittsburgh School of Medicine, Pennsylvania 15213, USA.
authors.forename: B R
authors.initials: BR
authors.lastname: Gastman
authors.forename: Y
authors.initials: Y
authors.lastname: Atarshi
authors.forename: T E
authors.initials: TE
authors.lastname: Reichert
authors.forename: T
authors.initials: T
authors.lastname: Saito
authors.forename: L
authors.initials: L
authors.lastname: Balkir
authors.forename: H
authors.initials: H
authors.lastname: Rabinowich
authors.forename: T L
authors.initials: TL
authors.lastname: Whiteside
mesh_terms: D017209:Apoptosis; D002294:Carcinoma, Squamous Cell / Q000737:chemistry*; D053222:Fas Ligand Protein; D006258:Head and Neck Neoplasms / Q000737:chemistry*; D006801:Humans; D015151:Immunoblotting; D019169:Jurkat Cells; D016246:Lymphocytes, Tumor-Infiltrating / Q000502:physiology*; D008562:Membrane Glycoproteins / Q000032:analysis* / Q000235:genetics / Q000502:physiology; D010649:Phenylalanine / Q000031:analogs & derivatives / Q000494:pharmacology; D012333:RNA, Messenger / Q000032:analysis; D013876:Thiophenes / Q000494:pharmacology; D014407:Tumor Cells, Cultured; D019014:fas Receptor / Q000032:analysis
chemical_list: C505661:FASLG protein, human; D053222:Fas Ligand Protein; D008562:Membrane Glycoproteins; D012333:RNA, Messenger; D013876:Thiophenes; D019014:fas Receptor; D010649:Phenylalanine; C080985:batimastat